- Home
- JBGS vs ACRS Comparison
JBGS vs ACRS Comparison
Compare JBGS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | ACRS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.7M | 748.6M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | JBGS | ACRS |
|---|---|---|
| Price | $14.41 | $5.35 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $10.20 |
| AVG Volume (30 Days) | 500.6K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.71 | $1.46 |
| 52 Week High | $24.30 | $5.88 |
Technical Indicators
Market Signals| Indicator | JBGS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 51.65 |
| Support Level | $14.13 | $4.13 |
| Resistance Level | $15.31 | $5.87 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 17.69 | 23.57 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.